17:22 , Dec 4, 2018 |  BioCentury  |  Finance

INKEF’s creative ambitions

With the appointment of Roel Bulthuis as managing director and head of the healthcare team, European VC INKEF Capital plans to take a more active role in healthcare company creation. Bulthuis was previously managing director...
20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

VSN16R: Phase II started

Canbex began a double-blind, placebo-controlled, dose-escalation, U.K. Phase II trial to evaluate 50-400 mg oral VSN16R daily or twice daily for 26 days in about 142 patients. Ipsen Group (Euronext:IPN; Pink:IPSEY, Boulogne-Billancourt, France) has an...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Canbex Therapeutics, Ipsen deal

Canbex granted Ipsen an exclusive option to acquire Canbex. The option is exercisable following the completion of a Phase IIa trial of VSN16R . The anti-spastic oral small molecule has completed a Phase I study...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Canbex Therapeutics management update

Canbex Therapeutics Ltd. , London, U.K.   Business: Autoimmune, Musculoskeletal   Hired: Alberto Lledo as CMO; he replaces Miroslav Ravic  ...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

VSN16R: Phase I started

Canbex began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending-doses of VSN16R in about 72 healthy volunteers. Canbex Therapeutics Ltd. , London, U.K.   Product: VSN16R   Business: Musculoskeletal  ...
07:00 , May 20, 2013 |  BioCentury  |  Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Canbex Therapeutics board of directors update

Canbex Therapeutics Ltd. , London, U.K.   Business: Autoimmune, Musculoskeletal   Appointed: Nilesh Kumar, director at Merck Serono Ventures  ...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Financial News

Canbex Therapeutics completes venture financing

Canbex Therapeutics Ltd. , London, U.K.   Business: Autoimmune, Musculoskeletal   Date completed: 4/8/13   Type: Venture financing   Raised: £2.1 million ($3.2 million)   Investors: Merck Serono Ventures; UCL Business; Wellcome Trust   Note:...